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Abstract
Atelectasis is a significant risk factor for the development of pneumonia, especially in pediatric
populations that are more prone to alveolar collapse or those who may have weakened muscular
tone. The Metaneb® System is a pneumatic, non-invasive physiotherapy technique that delivers
chest high frequency oscillations (CHFO). CHFO has been shown to enhance mucociliary
clearance of secretions and help resolve patchy atelectasis. This report describes the case of a 17
year old female who developed significant left sided atelectasis after extubation and was
effectively managed with complete resolution of her atelectasis with the Metaneb System,
obviating the need for reintubation.
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Introduction
Atelectasis, defined as airway collapse, resulting in non-aeration of affected lung regions is
common place in critically ill patients, and is a well known risk factor for the development
of pneumonia.1 There are several chest physiotherapy techniques (CPT) that have been
devised for reduction of atelectasis in non-ventilated patients; however none have been
deemed the standard of care for the management of this condition.2 The Intermittent
Percussive Ventilation (IPV®) device, developed by Dr. Forest M. Bird in the late1980’s, is
a ventilatory treatment technique that delivers small bursts of gas flow into the lung at high
rates. This causes airway pressures to oscillate at very small tidal volumes, and the airway
walls vibrate in unison with these oscillations.3 During the delivery of these small tidal
volumes, it is theorized that collapsed airways are opened and intrabronchial secretions are
mobilized.4 The Metaneb® System (Hill-Rom, Inc. Batesville, Indiana), which was FDA
approved in to be used in the hospital setting , is similar to the IPV® device and uses similar
engineering to provide the unique gas flow characteristics of IPV®, called chest high
frequency oscillations (CHFO) (Figure 1). CHFO is described as a pneumatic form of chest
physiotherapy that enhances mucociliary clearance and may resolve patchy atelectasis.5–7
The circuit interface used with the Metaneb® device is seen in Figure 2. The circuit consists
of a patient mouthpiece, nebulizer, venturi, and accessory tubing. The Metaneb® can be
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adjusted to deliver various levels of high frequency rates, pressure limits, and has the
capability to supply various levels of resistance on exhalation.
We report a case of a 17 year old female with > 80% dermatologic involvement of toxic
epidermal necrolysis and Pseudomonas pneumonia who developed worsening atelectasis
after extubation, and who was effectively managed with a Metaneb® device obviating the
need for reintubation. This study was reviewed and approved by our Institutional Review
Board.
Case Report
A 17 year old female with no prior medical history, reported to a referring institution
complaining of a sudden onset of headaches. Upon evaluation, she was found to have a right
basal ganglia intracerebral hemorrhage with mass effect and midline shift with an associated
left-sided hemiparesis. No neurosurgical intervention was undertaken, but she was started on
a regimen of phenytoin for seizure prophylaxis, which was then changed to levetiracetam.
Despite having discontinued the phenytoin, she developed a diffuse rash, fevers, and
generalized severe pain. Biopsy of the rash was taken by the Dermatology consultants
revealed Toxic Epidermal Necrolysis (TEN).
The patient was transferred to our burn intensive care unit with large surface area
involvement (>80% total body surface area) of her wounds and significant pain experienced
with wound care. On hospital day (HD) 2 on our unit, the decision was made by the surgical
team to electively intubate her for pain management and adequate wound care. On HD 3, the
patient was taken to the operating room for extensive debridement and xenografting of her
wounds. The patient tolerated the procedure well, and continued to be intubated for her
extensive wound care. On HD 8, the patient became febrile with an elevated white blood cell
count and left sided pulmonary infiltrate on chest x-ray (CXR). She was pan-cultured and
respiratory cultures grew Pseudomonas, for which she was started on intravenous
antibiotics.
The patient continued to improve with normalization of her CXR and laboratory values and
the decision was made to extubate her on HD 17 (See Figure 3). The patient tolerated the
procedure well, however within 24 hours was noted to have an elevated white count,
worsening physical exam with rhonchorous breath sounds on the left; greater than the right,
which correlated with radiologic findings. During this time, the patient maintained adequate
oxygenation, but had problems expectorating secretions because of an inability to cough
effectively, due both to generalized weakness as well as her recently developed hemiparesis.
Despite nebulized albuterol treatments and high flow oxygen therapy, her left sided
atelectasis continued to worsen (See Figure 4).
The decision was made to start her on breathing treatments using the Metaneb® device with
aerosolized normal saline. Treament with the Metaneb® device was given every two to three
hours for approximately ten minutes per treatment. Within four hours of starting the every 2
hour therapy, her atelectasis had partially improved (See Figure 5), and had completely
resolved by HD 21 (See Figure 6), with normalization of her white count. During this
episode of atelectasis, the patient was still on intravenous antibiotics that had been started
for her previously diagnosed pneumonia. The patient remained on antibiotics for a total of
14 days. The patient continued to do well, had improved physical exam findings and was
discharged to home on HD 25 with no further infectious or respiratory complications.
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Atelectasis is a significant risk factor for the development of pneumonia, especially in
patients that are more prone to alveolar collapse, such as pediatric populations or those who
may have weakened muscular tone.1–2,8 CHFO, via the Metaneb® device, is an effective
CPT modality for the management of atelectasis in non-ventilated patients, as shown in the
case of this patient with left sided hemiparesis. After just eight hours of initiating Metaneb®
system treatments, this patient had significant improvement in both radiologic and physical
exam findings. If the patient had required re-intubation because of worsening atelectasis and
pneumonia, her hospital stay could have been significantly extended, while placing her at
risk for increased morbidity and/or mortality.
The Metaneb® device maintains high frequency oscillatory percussive breaths during
inspiration and expiration to form a pressure gradient in small airways where secretions may
be trapped. The Metaneb® device employs a fixed orifice venturi to deliver the high
frequency percussive breaths whereas the IPV® device manufactured by Percussionaire®
uses a sliding venturi system. In theory, both venturi systems are designed and engineered to
provide high frequency percussions during both inspiration and exhalation which results in a
pressure gradient. It is theorized that the pressure gradient that is created by these unique
systems accelerates expiratory airflow allowing any secretions in the small airways to move
up and into the larger airways, making it easier for patients to expectorate the secretions or
to be suctioned via an artificial airway.7 At the same time, hyperinflation during the
treatment with this device may help the patient to breath deep and cough effectively.
Improvement in atelectasis in patients treated with IPV® or the Metaneb® System may be
due to the increased efficiency of ventilation into the lungs via the high frequency
oscillatory percussive breaths. In patients with bronchiectasis, short term IPV® has been
shown to be as effective as chest physiotherapy with less discomfort for the patients
receiving the therapy.9–10 Further studies need to be done to better understand how the
Metaneb® system and IPV® treatments can be used to improve ventilation and mucous
clearance in non-intubated patients.
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Continuous high frequency oscillations are delivered during both inspiration and expiration
(With permission from Hill Rom®)
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Patient interface between the patient and Metaneb® (With permission from Hill Rom®)
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CXR on HD 17
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CXR on HD 19 showing worsening left-sided atelectasis
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CXR just four hours after the initiation of CHFO treatment
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CXR appearance on HD 21, two days after starting CHFO
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